Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab

BACKGROUND: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2. METHODS: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Thornton, Jeanine Rempe, Harel, Asaff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318946/
https://www.ncbi.nlm.nih.gov/pubmed/32622338
http://dx.doi.org/10.1016/j.msard.2020.102341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318946/
https://www.ncbi.nlm.nih.gov/pubmed/32622338
http://dx.doi.org/10.1016/j.msard.2020.102341

Ejemplares similares